Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.

Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.

BACKGROUND:Results from phase III clinical trial CheckMate 025 have established nivolumab as the standard of care for treatment of metastatic renal-cell carcinoma (mRCC) after VEGF inhibitor failure; however, elderly patients are under-represented in the registration trial and little is known about...

Full description

Bibliographic Details
Main Authors: Maria Giuseppa Vitale, Sarah Scagliarini, Luca Galli, Sandro Pignata, Giovanni Lo Re, Alfredo Berruti, Carlotta Defferrari, Massimiliano Spada, Cristina Masini, Daniele Santini, Libero Ciuffreda, Enzo Maria Ruggeri, Carmelo Bengala, Lorenzo Livi, Daniele Fagnani, Andrea Bonetti, Lucio Giustini, Alketa Hamzaj, Giuseppe Procopio, Claudia Caserta, Roberto Sabbatini
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6034807?pdf=render

Internet

http://europepmc.org/articles/PMC6034807?pdf=render

Similar Items